Connect Biopharma Holdings Ltd
NASDAQ:CNTB

Watchlist Manager
Connect Biopharma Holdings Ltd Logo
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Watchlist
Price: 0.9509 USD -4.19% Market Closed
Market Cap: 52.5m USD
Have any thoughts about
Connect Biopharma Holdings Ltd?
Write Note

Connect Biopharma Holdings Ltd
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Connect Biopharma Holdings Ltd
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Net Change in Cash
ÂĄ27m
CAGR 3-Years
-66%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Change in Cash
-ÂĄ5.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Change in Cash
ÂĄ381.7m
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Change in Cash
-ÂĄ1.4B
CAGR 3-Years
N/A
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Change in Cash
ÂĄ362.5m
CAGR 3-Years
-50%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Net Change in Cash
-ÂĄ705.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Connect Biopharma Holdings Ltd
Glance View

Market Cap
52.5m USD
Industry
Biotechnology

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.

CNTB Intrinsic Value
0.3275 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is Connect Biopharma Holdings Ltd's Net Change in Cash?
Net Change in Cash
27m CNY

Based on the financial report for Dec 31, 2023, Connect Biopharma Holdings Ltd's Net Change in Cash amounts to 27m CNY.

What is Connect Biopharma Holdings Ltd's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-40%

The average annual Net Change in Cash growth rates for Connect Biopharma Holdings Ltd have been -66% over the past three years , -40% over the past five years .

Back to Top